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ABSTRACT
Objective: The aim of this study is to analyze the association of serum lipids and lipoproteins in patients with angina pectoris.
Methods: A total of 110 patients (60 males and 50 females) with angina pectoris aged (55±5) years and 80 healthy controls (43 males and 
37 females) aged (45±4) years were enrolled in this case-control study from the clinic of Al Yarmouk Hospital. Serum lipids, lipoprotein(a) [Lp(a)], 
apolipoprotein-A1, and apolipoprotein-B levels were measured and studied.
Results: The results of this study showed that increased odds of angina pectoris were associated with increased serum levels of Lp(a) more than 
serum levels of apolipoprotein-B.
Conclusions: Analysis of Lp(a) may be an important determinant of cardiovascular disease diagnosis.
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INTRODUCTION
Cardiovascular diseases are the most common cause of death worldwide. 
These facts advocated the researchers to modify the strategies used for 
prediction, prevention, and treatment of cardiovascular diseases.
Inflammatory mechanisms play an important role in the pathogenesis and 
prognosis of atherosclerosis. Many atherogenic lipoproteins imply a critical 
role in the proinflammatory reaction such as apolipoprotein B, oxidized 
low-density lipoprotein (LDL), and lipoprotein(a) [Lp(a)]. Whereas anti-
atherogenic lipoproteins such as high-density lipoprotein and exert anti-
inflammatory function [1].
LDL cholesterol (LDL-C) is one of the most common predictors of 
cardiovascular diseases, but many studied suggested that apolipoprotein-B 
(apo-B) and non-high-density lipoprotein cholesterol (non-HDL-C) may 
be more precisely predict the risk of cardiovascular disease [2].
Apo-B is present as a single molecule in low-, intermediate-, and very 
LDL while apolipoprotein-A1 (apo-A1) is the major apolipoprotein 
associated with HDL. The ratio between the concentrations of apo-B 
and apo-A1 (apo-B/apo-A1) may reflect the balance between the 
opposing processes of arterial internalization of cholesterol and the 
reverse transport of cholesterol back to the liver [3,4].
Lp(a) is composed of a LDL particle and a glycoprotein molecule known 
as apolipoprotein (a) [apo-(a)], which is structurally homologous to 
plasminogen (a) [5]. Therefore, Lp(a) has a tendency to exert both 
proatherogenic and prothrombotic effects(impaired fibrinolysis) 
in multiple stages of the atherosclerosis process, some of which are 
apo-(a) dependent other are related to the LDL component [6].
Lp(a) does not bind to the LDL - receptor, and accordingly, its level in 
circulation is not determined by the particle clearance but is determined 
by its synthesis [7,8].
The goal of this case–control study was to measure the association 
(odds ratio [OR]) and the percent changes in relation to biochemical 
variables in patients with stable angina, focusing on serum levels of 
lipids, and lipoproteins.
METHODS
A total of 110 patients (60 males and 50 females), with stable angina 
pectoris aged (55±5) years and 80 healthy controls (43 males and 
37 females), aged (45±4) years were recruited from the clinic of Al 
yarmouk hospital in Iraq. All participants evaluated through collecting 
medical histories and routine clinical laboratory tests. Exclusion 
criteria included patients with diabetes, liver disease, renal failure, and 
heart failure.
At fasting state, laboratory analyses of serum total cholesterol (TC), 
HDL-C, and triglycerides (TGs) levels measured using standard methods 
on automated analyzer.
In patients with TGs, ≤400 mg/dl, LDL-C was calculating according 
to Friedewald’s formula [9], while non-HDL-C was calculating by 
subtracting HDL-C from TC [10].
LDL-C (mg/dl)=TC-[(TG/5)+HDL-C]
Non-HDL-C (mg/dl)=TC-HDL-C
Lp (a), apo-A1, apo-B, and C-reactive protein (CRP) levels measured 
using enzyme-linked immunosorbent assay.
All eligible participants provided written informed consent to partake 
in this study. The study protocol conforms to the ethical guidelines and 
approved by the Institution’s Ethics Committee.
All numerical data gave as mean ± standard deviation with 95% 
confidence interval (CI). Comparisons of continuous variables were 
assessed by Student’s t-test, p values of (0<0.05) were regarded to 
be statistically significant. All statistical analyses performed using 
Microsoft excel and SPSS version 18.0 for windows.
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RESULTS
The demographic and biochemical data of the studied participants 
stratified in Table 1.
Notably, the mean serum levels of lipids and lipoproteins that included 
TC, TG, LDL-C, non-HDL-C, apo-B and Lp(a) were considerably higher in 
patients with angina pectoris than in control subjects. Conversely, the 
mean serum levels of HDL-C and apo-A1 were substantially lower in 
cases as compared with control subjects (Table 1).
In Fig. 1, the plotted bar graph of the percent changes in lipid fractions 
and lipoproteins for patients with stable angina as related to healthy 
control showed high percent elevation in Lp(a) level and low percent 
elevation in apo-B level (+133.88 %, +9.32%), respectively. As well 
there was a high percent elevation noted in CRP level (+167.5%) which 
is an inflammatory biomarker.
The association or correlation between the presence of angina and the 
increased levels of most interested lipids and lipoproteins more than 
normal levels were estimated using OR as shown in Table 2, in which 
high significant positive correlation was found between the selected 
variables and the presence of angina.
Moreover, the odds of increased level of Lp(a) was 2.2 times among 
cases than control (OR=2.2; 95% CI=1.53-3.22, p<0.001), while the 
odds of increased level of apo-B was 1.87 times among cases than 
control (OR=1.87; 95% CI=1.16-2.36, p<0.001).
DISCUSSION
Low-density lipoprotein-cholesterol is a well-known risk factor for 
cardiovascular diseases, physicians in worldwide direct first-line of 
treatment toward lowering LDL-C.
This study denoted that increased serum levels of non-HDL-C, LDL-C, 
apo-B, and Lp(a) were comparably and consistently associated with 
increased odds of angina attack, but the odds of increased level of Lp(a) 
were more than the odds of increased level of apo-B; this may lead to 
suggest that the level of Lp(a) may be more useful for diagnosis and 
prognosis of angina than apo-B level.
As well high percent of increased level of Lp(a) among other lipids 
and lipoprotein in patients with stable angina may confirm the above 
suggestion.
There were many controversial opinions focuses on the superiority of 
the measurement of LDL-C, non-HDL, apo-bor Lp(a) that are consisted 
with the results of this study or contrasted.
First, LDL cholesterol calculated using Friedewald’s formula 
that is accurate only when serum triglyceride levels lower than 
400 mg/dl, so this equation is particularly inaccurate once the patients 
have triglycerides levels higher than 400 mg/dl or have type III 
hyperlipoproteinemia [11].
Second, non-HDL-C calculated to provide an estimate of cholesterol 
levels in the atherogenic particles including low-, intermediate-, and 
very LDL. Arsenault et al., in 2009, suggested that non-HDL-C was 
associated with coronary heart disease risk independent of their 
plasma LDL-C levels [12].
Moreover, the National Cholesterol Education Program Adult Treatment 
Panel III guideline in 2001 mentioned that non-HDL-C is not a novel 
concept and recommended as a secondary target for patients with 
triglycerides levels >200 mg/dl, i.e., non-HDL-C is useful for estimating 
LDL-C atherogenicity in patients with triglycerides levels outside of 
Friedewald’s formula’s range [13].
Third, the measurement of apo-B level in some study suggests being 
superior to non-HDL-C level and should be introduced into routine 
care [14], while others do not support routine measurement of 
apo-B [15].
Likewise, the Joint European Society of Cardiology/European 
Atherosclerosis Society guidelines on the management of dyslipidemias 
recommended the measurement of apo-B as a better index of 
adequacy of LDL-lowering therapy than measurement of LDL-C. If the 
measurements of apo-B are not available, the guidelines consider the 
use of non-HDL-C [16].
Table 1: The demographic and clinical data of the studied 
participants
Variables Control Angina pectorispatients
Number 80 110
Gender (male/female) 43/37 60/50
Age (year) 45±4 55±5
CRP (mg/L) 1.54±1.03 4.12±1.15***
TC (mmol/L) 3.77±0.525 5.134±0.533***
LDL-C (mmol/L) 1.923±0.4 2.912±0.527***
HDL-C (mmol/L) 1.258±0.272 0.921±0.33***
TG (mmol/L) 1.538±0.21 2.332±0.278***
Non-HDL-C (mmol/L) 2.469±0.321 4.158±0.383***
Apo- A1 (mg/dl) 155.6±10.3 143.7±15.5***
Apo- B (mg/dl) 96.4±12.6 105.38±18.4***
Lp(a) (mg/dl) 12.28±4.8 28.72±8.46***
Data are presented as mean±SD (standard deviation) for continuous variables, 
***High significant difference p˂0.001 versus control, mg/L: Milligram 
per liter, mg/dl: Milligram per deciliter, mmol/L: Millimole per liter, 
Number: Sample size of the participants, CRP: C-reactive protein, TC: Total 
cholesterol, LDL-C: Low-density lipoprotein cholesterol, HDL-C: High-density 
lipoprotein cholesterol, Non-HDL-C: Non-high density lipoprotein cholesterol, 
TG: Triglyceride, Apo-A1: Apolipoprotein-A1, Apo-B: Apolipoprotein-B,  
Lp(a): Lipoprotein(a)
Table 2: Association between the presence of stable angina and 
the inceased levels of lipids and lipoprotein
Parameters OR (95% CI) p value
Apo-B 1.87 (1.16-2.36) ***
LDL-C 2.05 (1.22-2.52) ***
Non-HDL-C 2.12 (1.4-2.87) ***
Lp(a) 2.2 (1.53-3.22) ***
Sample size (n)=80 for control subjects, (n)=110 for angina pectoris patients, 
OR: Odds ratio, ***High significant correlation p˂0.001, CI: Confidence 
interval, Apo-B: Apolipoprotein-B, LDL-C: Low-density lipoprotein cholesterol, 
Non-HDL-C: Non-high density lipoprotein cholesterol, Lp(a): Lipoprotein(a)
Fig. 1: Percent changes in lipids, lipoproteins, and C-reactive 
protein for patients with angina pectoris as compared with 
control subjects. Sample size (n)=80 for control subjects, (n)=110 
for angina pectoris patients, HDL-C: High-density lipoprotein 
cholesterol, Non-HDL-C: Non-high density lipoprotein cholesterol, 
Apo-A1: Apolipoprotein-A1, Apo-B: Apolipoprotein-B, TC: Total 
cholesterol, TG : Triglyceride, LDL-C: Low density lipoprotein 
cholesterol, Lp(a): Lipoprotein(a), CRP: C-reactive protein
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Fourth, the elevated level of Lp(a) was strongly correlated with the 
degree of coronary atherosclerosis as suggested by Batalla et al. [17] 
and with the restenosis after revascularization as mentioned by Miyata 
et al. [18]. However, Skinner et al. not confirmed the prognostic value of 
Lp(a) levels in patients with coronary artery disease [19].
Moreover, the guidance’s of treatment toward lowering Lp(a) in 
patients with cardiovascular diseases may be controversial; some study 
revealed that the reduction of Lp(a) level using niacin treatment lack its 
efficacy for lowering vascular risk [20]. Another study mentioned the 
safety of lowering Lp(a) levels in patients with coronary heart disease 
using acetrapib, a cholesterol ester transfer protein inhibitor [21].
Another drug like statin [22] or plant like blend of Moringa oleifera 
could be using for lowering blood levels of cholesterol and triglyceride 
either by inhibiting the de novo synthesis or by inhibiting the intestinal 
absorption of cholesterol [23].
CONCLUSION
Among lipids and lipoproteins variables, although Non-HDL-C and 
LDL-C measurements provide a convenient, valuable, and clinically 
plausible end point but the measurement of Lp(a) is more accurate 
than others for the diagnosis and prognosis of atherosclerosis-related 
diseases.
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